Anesthesiology 79:1392–1401, 1993 © 1993 American Society of Anesthesiologists, Inc. J. B. Lippincott Company, Philadelphia

Ion Channels in Vascular Smooth Muscle

Physiology and Pharmacology

Zeljko J. Bosnjak, Ph.D.

VASCULAR smooth muscle regulation is accomplished by several major regulatory mechanisms, including: (1) neural transmitters (*e.g.*, norepinephrine [NE], adenosine triphosphate [ATP], and nitric oxide [NO]); (2) endothelial factors (*e.g.*, endothelium-derived relaxing factor [EDRF], endothelium-derived hyperpolarizing factor [EDHF], and endothelins); (3) metabolic influences (*e.g.*, oxygen and carbon dioxide tension, *p*H, and temperature); (4) humoral agents (*e.g.*, NE, epinephrine [E], histamine, angiotensin II [Ang II], vasopressin [ADH], vasoactive intestinal peptide [VIP], atrial natriuretic peptide [ANP], and others); and (5) myogenic influences (*e.g.*, intraluminal pressure and stretch).

The pathways that are responsible for the excitation of vascular smooth muscle include: (1) nerve stimulation-induced contractions without change in smooth muscle membrane potential; (2) neurotransmitter-induced smooth muscle action potential generation after nerve stimulation leading to contraction; (3) persistent depolarization of the smooth muscle and muscle contraction caused by neurotransmitters or other vasoactive substances and transmural pressure; and (4) contractions initiated by spontaneous action potentials generated by some smooth muscle cells acting as pacemakers, and the subsequent spread of excitation *via* gap junctions and cell-to-cell conduction.

A number of the above-listed categories may be superimposed on, or occur as a consequence of, previous excitation, such as a steady level of depolarization. Moreover, some smooth muscle cells may not have ac-

Received from the Departments of Anesthesiology and Physiology, The Medical College of Wisconsin, Milwaukee, Wisconsin. Accepted for publication July 13, 1993. Supported in part by National Institutes of Health grants HL01901 and HL34708 and Anesthesiology Research Training grant GM08377.

Address reprint requests to Professor Bosnjak: The Medical College of Wisconsin, 8701 West Watertown Plank Road, Milwaukee, Wisconsin 53226.

cess to neurally released neurotransmitters, but may be coupled to other cells by a gap junction. Therefore, there is a considerable qualitative and quantitative difference throughout the vascular beds because of the multiplicity of vascular smooth muscle excitations, including the type and density of innervation, presence of pacemaker cells, intraluminal pressure, type and density of receptors, number of low-resistance gap junctions, and type and number of ion channels (fig. 1).

For the most part, two regulatory systems control vascular smooth muscle tone: endothelium and the sympathetic nervous system. Modulation of vascular tone by the sympathetic nervous system reflects the perfusion requirements of the intact organism after input from the peripheral and central baro- and chemoreceptors to the central nervous system pressor centers. The endothelium influences the tone by releasing a number of vasoactive factors in response to a variety of changes in the chemical and physical environment around the specific vascular bed. There are several possible interactions between factors released from neural endings and endothelium, although these interactions depend on the relative distribution of these regulatory systems in a given vessel bed.¹

The key mechanism in the interaction between the two regulatory systems involves the alteration in the concentration of ionized calcium (Ca^{2+}) in the cytoplasm of the smooth muscle cell. At rest, the intracellular Ca^{2+} concentration in smooth muscle is approximately 0.1 μ M, and, during the maximum activation, it ranges from 1 to 10 μ M. Depolarization of the vascular smooth muscle membrane by high extracellular K^+ or agonists causes a relatively rapid increase in cytoplasmic Ca^{2+} , which then declines somewhat to a new level during persistent depolarization. The principle source of the Ca^{2+} is likely to be Ca^{2+} influx through the sarcolemma, although Ca^{2+} release from the endoplasmic reticulum is also present. On the other hand, Ca^{2+} mobilization by a number of different li-

gands may start with a breakdown of membrane phospholipids and the formation of inositol 1,4,5-triphosphate (IP₃) and diacylglycerol (DAG). In vascular smooth muscle, one of the major roles of IP₃ is to release Ca^{2+} from the sarcoplasmic reticulum (SR).


Influx of Ca²⁺ from the extracellular space occurs through the voltage-operated channels (VOC), receptor-operated channels (ROC), and nonselective cation channel (NSCC), and by reversed Na⁺/Ca²⁺ exchange mechanism. Additional calcium is released from the mitochondria and sarcoplasmic reticulum (SR; fig. 2). The voltage-gated calcium channels are subdivided into long-lasting (L-), transient (T-), and resting (R-) types of channels. The channels responsible for the release of Ca2+ from the SR are ryanodine channels (Ca²⁺-induced Ca²⁺ release channel, caffeine sensitive) and IP3 channels (heparin sensitive). Factors contributing to a decrease in intracellular calcium include calcium pumps in the sarcolemma, endoplasmic reticulum, and mitochondria, along with a forward mode of the Na⁺/Ca²⁺ exchanger (fig. 2).

Receptors

The stimulation of different receptors in smooth muscle cells by agents such as norepinephrine, acetylcholine, and serotonin induces the breakdown of polyphosphoinositides.³ This process initially involves the activation of phospholipase C enzyme, which hydrolyzes phosphatidylinositol 4,5 bisphosphate (PIP₂), leading to the production of IP₃ and 1,2-diacylglycerol (DAG). Both compounds are intracellular second messengers. From the cell membrane, the IP3 diffuses to the SR and mobilizes intracellular Ca2+. It is generally accepted that IP₃-sensitive and IP₃-insensitive Ca²⁺ stores can coexist in the same smooth muscle cells with the two pools being interdependent.⁴ It was proposed that caffeine could deplete a caffeine- (and Ca²⁺-) sensitive pool, and also indirectly affect the IP₃ pool. The increase in ionized Ca²⁺ appears to be responsible for the phasic component of the smooth muscle contractile response. However, to obtain the maximal and longer contractile response from the smooth muscle, a tonic component is necessary that requires the activation of ROC or VOC.² Both types of contractions could be induced, for example, by simultaneous stimulation of α_1 and α_2 adrenoceptors leading to Ca^{2+} release from intracellular stores and Ca2+ influx, respectively. It should be pointed out, however, that vascular smooth muscle contraction is generally tonic in nature. The blood vessels, for instance, unlike cardiac and skeletal muscle, can remain in a contracted state for prolonged periods of time.

Most blood vessels have both α_1 - and α_2 -adrenergic subtypes, and their stimulation by agonists leads to

Fig. 1. Vascular smooth muscle cells have both plasma membrane-bound and intracellular receptors. The major sarcolemmal receptors include α -adrenergic, β -adrenergic, and muscarinic cholinergic receptors. Also present are the receptors for ATP, endothelin, serotonin, histamine, angiotensin II, VIP, stretch, and others. Intracellular receptors responsible for the release of Ca2+ from the intracellular stores include inositol 1,4,5triphosphate (IP3) and ryanodine (Ry) receptors. In addition, nitric oxide (NO) will enhance the activity of cellular guanylyl cyclase. Along with channels for Ca²⁺, Cl⁻, K⁺, and Na⁺, the sarcolemma of the vascular smooth muscle also contains a nonspecific cation channel (NSCC). The ionic exchangers in sarcolemma include Na⁺/Ca²⁺ H_{co3}-/Cl⁻, and Na⁺/H⁺ exchanger; and the ATP-dependent pumps are Na⁺/K⁺ and Ca²⁺ pumps with H⁺ or K⁺ as a counterion. Gap junctions are formed between the cells, and are responsible for the ionic exchange between cells and electrotonic coupling.






Fig. 2. Diagram depicting different Ca2+ pathways in the sarcolemma and sarcoplasmic reticulum (SR) of the vascular smooth muscle cell. Different pathways contributing to an increase in intracellular Ca2+ are depicted on the left of this schematic diagram. Influx of Ca2+ from the outside of vascular smooth muscle cell occurs via voltage-operated channels (VOC), receptor-operated channels (ROC), reversed Na⁺/Ca²⁺ exchanger, and nonspecific cation channel (NSCC). Although some Ca2+ can be derived from mitochondria (M), most of the Ca2+ supplied for contraction from intracellular stores comes from the SR after the stimulation of ryanodine (Ry) or inositol 1,4,5-triphosphate (IP₃) channels. Factors contributing to a decrease in intracellular Ca²⁺ are shown on the right, and include Ca²⁺ pump and forward mode of the Na⁺/Ca²⁺ exchanger in sarcolemma. An active reuptake by the mitochondria and the SR also contribute to the cellular sequestration of ionized Ca2+.

smooth muscle contraction. The relative proportion of adrenergic subtypes and their numbers vary considerably between different vascular beds. Norepinephrine, when applied exogenously, either depolarizes the sarcolemma or has no effect on the membrane potential of the smooth muscle cells. Because norepinephrine, with few exceptions (such as cerebral arteries), consistently evokes contraction, depolarization of the membrane is not always a prerequisite for the initiation of contraction after α_1 adrenoceptor stimulation. An α_2 adrenoceptor stimulation (coupled to G protein) activates the membrane-associated Ca2+ channel to produce Ca2+ influx and cellular depolarization. By stimulating α_1 receptors, norepinephrine activates phosphatidylinositide hydrolysis by phospholipase C, which, in turn, leads to the generation of two second messengers: IP3 and DAG.⁵ After the release of Ca²⁺ from the SR, intracellular Ca2+ leads to an increase in chloride conduction and the opening of nonspecific cation channels and subsequent membrane depolarization.6 Equilibrium potentials for both Na⁺ ($E_{Na} = +50 \text{ mV}$) and Cl^{-} (E_{Cl} = -20 mV) are more positive than the resting membrane potential ($E_m = -40 \text{ to } -55 \text{ mV}$). In addition, norepinephrine appears to enhance voltage-dependent Ca2+ channel current by increasing the open-state probability (Po) of single Ca2+ channels, but the membrane depolarization induced by activation of Ca2+ activated chloride channels is

the prerequisite for further stimulation of Ca²⁺ channels in response to norepinephrine. Furthermore, norepinephrine may induce a shift in the relationship between P_o of the voltage-gated Ca²⁺ channel and the membrane potential.⁸ At a given potential, more of the voltage-sensitive Ca²⁺ channels are open in the presence of norepinephrine. Therefore, norepinephrine increases intracellular Ca²⁺ concentration *via* release of Ca²⁺ from intracellular stores, stimulation of Ca²⁺ influx through receptor-operated channel, and activation of voltage-dependent Ca²⁺ channels.²

 β -Adrenergic receptors are also found in most blood vessels, and, when stimulated, they inhibit contraction of the vascular smooth muscle. β_1 and β_2 -adrenoreceptor subtypes are coupled to adenylyl cyclase via G_s protein. In turn, adenylyl cyclase mediates the conversion of ATP to cAMP that can lead to vasodilation. In some cells, this inhibition is essentially ineffective, because α_2 receptors are coupled to the same adenylyl cyclase via G_1 protein that inhibits cAMP production. Nevertheless, some vessels only dilate in the presence of NE, most likely because of a specific adrenoceptor population in the sarcolemma.

Stimulation of muscarinic cholinergic receptors on the smooth muscle cells will cause contractions that are likely to be mediated by phosphoinositides. This direct effect will not be seen in most vessels, because ACh will release EDRF from the endothelial cells at the same time. Although vasodilation will be dominant in most arteries, peripheral veins may dilate only with lower levels of ACh and constrict at higher concentrations.

Both norepinephrine and ATP are released from functional sympathetic nerve terminals. The ATP can act from intra- and extracellular sites on the smooth muscle cells. From intracellular sites, ATP activates voltage-dependent Ca²⁺ channels, and, from extracellular sites, ATP acts on the purinergic-2 (P-2) receptor and, possibly, on the voltage-dependent Ca²⁺ channels. ATP can depolarize the membrane of vascular smooth muscle cells (an exception appears to be coronary artery) by binding to the P-2 receptors that are coupled to Ca²⁺ channel producing contraction.

Vasopressin (ADH) triggers IP₃-sensitive release of Ca^{2+} from internal stores,⁴ which then propagates throughout the cell as an intracellular Ca^{2+} wave, and activates its own release through Ca^{2+} -induced release of Ca^{2+} by diffusing to remote Ca^{2+} release sites. In addition, vasopressin can block the ATP-sensitive potassium channels (K_{ATP}) , leading to depolarization of smooth muscle cell, and subsequent contraction.

The sensitivity of vascular smooth muscle to Ca²⁺ antagonists varies depending on the vascular bed, vessel size, subtype of receptors present, and affinity of receptor-operated channels for the Ca²⁺ blocker. It appears that voltage-operated channels are generally more sensitive to Ca²⁺ antagonists than receptor-operated channels.¹⁰

While the underlying mechanism of angiotensin II effects on vascular smooth muscle are not fully understood, it appears that angiotensin II contracts the smooth muscle by stimulating Ca²⁺ influx *via* voltage-dependent Ca²⁺ channels. ^{11,12} This action may be mediated by G protein, and occurs with or without depolarization. In addition, angiotensin II also activates the formation of IP₃ and DAG through a G protein-mediated activation of phospolipase C. In addition to these actions, angiotensin II was shown to block K⁺ currents. ¹³

Vasoactive intestinal peptide (VIP) has a powerful ability to relax vascular and nonvascular smooth muscle. The VIP binds to a specific membrane receptor and selectively stimulates adenylyl cyclase to promote the accumulation of the cAMP and smooth muscle relaxation.

Endothelin-1 (ET-1) is a powerful vasoactive peptide released by endothelial cells¹⁴ that activates ET-1 receptors in smooth muscle. Stimulation of ET-1 recep-

tors can produce phospholipase C activation, which leads to stimulation of inositol phosphate turnover and the diacylglycerol production. This leads to stimulation of protein kinase C, which induces opening of Ca²⁺ channels. In addition, ET-1 releases Ca2+ from the SR through an IP3 response, which acts as a second messenger in modulating the membrane currents.¹⁵ The elevated intracellular Ca2+ is responsible for a sustained activation of Cl⁻ channel current, which depolarizes the membrane and is responsible for prolonged Ca²⁺ influx, or nonselective cation current and contraction. 16 Therefore, depending on the smooth muscle, ET-1-induced vasoconstriction can be initiated by Ca2+ influx across the sarcolemma (both Ca2+ selective and nonselective), or by IP₃-triggered release of Ca²⁺ from endoplasmic reticular stores. An additional effect of ET-1 on smooth muscle is increased myofilament Ca²⁺ sensitivity by a G protein-dependent pathway. 17,18 In addition to ET-1, other endothelium-derived peptides have been subsequently described, including ET-2, ET-3, and sarafotoxin. 19

If the intravascular pressure is elevated, most vessels respond by increasing smooth muscle tone, and, if the pressure is reduced, they vasodilate. The mechanism of the initiation of the myogenic response to increased or decreased transmural pressure or stretch is not known. Membrane potentials of smooth muscle cells measured in vitro range between -60 and -75 mV, and those measured in vivo are between -40 and -55mV.7 When isolated arteries are exposed to physiologic intraluminal pressures, they depolarize (to -40 to -55mV) and develop tone. There are a number of proposed mechanisms of intravascular pressure or stretch-induced alterations in vascular smooth muscle activation.²⁰ Some of the mechanisms include: (1) stretchinduced alterations in sarcolemmal properties, and subsequent activation or inhibition of the net inward current, or specific modulation of the signal coupling pathway within the smooth muscle cell; (2) lengthinduced alterations in contractile protein function; and (3) pressure and/or stretch-induced modulation of endothelial function.

Because the membrane potential of arterial smooth muscle cells *in vivo* falls in the range in which the current through the voltage-operated Ca^{2+} channels is highly voltage dependent, this current is likely to play a significant role in the maintenance of vascular tone. Depolarizations up to -40 mV activate and maintain inward Ca^{2+} current that does not significantly inactivate. It was shown that the P_0 of Ca^{2+} channel increases

exponentially with membrane depolarization between -60 and -40 mV.²¹ Between these potentials, a membrane hyperpolarization of only 2 mV could decrease P_o and, therefore, Ca^{2+} entry by approximately 30%.

Exchangers and Pumps

The membrane of vascular smooth muscle also contains Na⁺/H⁺, H_{CO3}⁻/Cl⁻, and Na⁺/Ca²⁺ exchangers, as well as the Na⁺/K⁺ and Ca²⁺ pump.²² The Ca²⁺ pump is stimulated by agents that increase cGMP (e.g., ANF, EDRF, and nitrovasodilators).²³ On the other hand, increases in K⁺ conductance as a result of activation of any of the K⁺ channels will lead to membrane hyperpolarization and inactivation of voltage-operated Ca²⁺ channels, and enhanced Ca²⁺ efflux via Na⁺/Ca²⁺ exchanger.²⁴ It was shown that Na⁺/Ca²⁺ exchange is dependent on membrane potential, with membrane depolarization decreasing the net Ca²⁺ extrusion by the exchanger.²⁴

Channels

Calcium Channels

At least two types of Ca²⁺ currents are present in vascular smooth muscle; L-type (long lasting) and T-type (transient). The T-type current activates and inactivates relatively rapidly at more negative potentials, and its inactivation is monoexponential and slowly voltage dependent. This current is not sensitive to classic Ca2+ channel blockers, as compared with the L-type current. The L-type Ca2+ channel inactivation is both voltage and Ca²⁺ dependent, and, therefore, biexponential. In addition, the slow Ca2+ channel current is abolished when the production of ATP is inhibited. 25 A new type of Ca2+ channel, called R-type (resting), was recently described in aortic and renal smooth muscle cells.26 This type of channel is apparently responsible for the sustained increase of Ca²⁺ during tonic contraction of smooth muscle that occurs during depolarization of the cell membrane in the presence of high levels of extracellular K⁺.

Phosphorylation of the Ca²⁺ slow channel protein can be either excitatory (proteinkinase C, PK-C) or inhibitory (cAMP-PK and cGMP-PK). For instance, angiotensin II activates the PL-C *via* a G protein, and PL-C stimulates PI turnover, leading to production of IP₃ and DAG. DAG activates PK-C to phosphorylate a number of proteins, including the Ca²⁺ slow channel, and to


stimulate Ca²⁺ influx.²⁵ As to the inhibitory role of cyclic nucleotides in regulation of intracellular Ca²⁺, activation of A-cyclase or G-cyclase by agents such as β -adrenergic agonists, prostacycline, or atrial natriuretic factor (ANF), or directly by agents like nitroprusside and EDRF, leads to an increase in cyclic AMP and cyclic GMP and activation of cA-PK and cG-PK. These kinases are responsible for phosphorylation of Ca²⁺ channels, which leads to inhibition of calcium channel opening and phosphorylation of K⁺ channels, leading to stimulation of K⁺ channel opening. ATP is required for activity of the channel, either by binding to the channel itself or via phosphorylation.25 In addition, the Ca2+ influx will be influenced by intracellular Ca²⁺ (increases in cytosolic Ca²⁺ accelerate the inactivation process of the Ca2+ channel, as shown in fig. 3) and membrane potential (depolarization will activate receptor-operated channels). Inhibition of Ca²⁺ slow channels, and stimulation of K⁺ channels, would inhibit Ca2+ influx and lower intracellular Ca2+. In addition to Ca2+ and K+ channels, cA-PK and cG-PK phosphorylate the Na⁺/Ca²⁺ exchanger and the sarcolemmal Ca²⁺-ATPase to stimulate the Ca²⁺ pump, and, therefore, can enhance activities of all three Ca2+-removal systems in vascular smooth muscle, producing vasodilation.^{25,27,28} In myocardial cells, however, Ca²⁺ channel phosphorylation by the cAMP-dependent protein kinase leads to an opposite effect, i.e., an increase in Ca2+ influx. The effects of phosphorylation by a cGMP-PK are similar in cardiac and smooth muscle cells.

Potassium Channels

In different vascular smooth muscles, a variety of macroscopic K^+ currents have been detected, including: (1) Ca^{2+} -activated K^+ current; (2) delayed rectifier K^+ current; (3) ATP-sensitive K^+ current; (4) inward rectifier K^+ current; and (5) background K^+ current. 26,29,30

The major outward current in vascular smooth muscle in response to membrane depolarization is carried by the large conductance Ca^{2+} -activated potassium channel (K_{Ca}). The P_{o} of this channel is relatively low at resting membrane potential, but increases in proportion to membrane depolarization and elevation of intracellular Ca^{2+} concentration. 31,32 An increase in K^{+} efflux would cause membrane hyperpolarization, reduce the opening probability of voltage-dependent Ca^{2+} channels, and produce subsequent vascular relaxation

Fig. 3. Schematic diagram of some of the effects of elevated intracellular Ca^{2+} . The Ca^{2+} can release SR Ca^{2+} stores through Ca^{2+} -activated Ca^{2+} release. In addition, Ca^{2+} activates sarcolemmal chloride and nonselective cation channels (NSCC) at negative membrane potentials (E_m) , and K^+ channels at more positive membrane potentials. Moreover, cytosolic Ca^{2+} accelerates the inactivation process of the sarcolemmal Ca^{2+} channel.



These channels appear to play a role in a vasodilating feedback pathway that is activated by pressure, intracellular free Ca2+, or membrane depolarization.33 The open time and frequency of opening of K_{Ca} channels are increased by 5'-GMP, a major metabolite of cGMP. The agents that increase the level of cGMP (ANF, NO, and nitrovasodilators) may, therefore, indirectly stimulate the K_{Ca}. Some of the other modulatory agents for these channels include norepinephrine, histamine, acetylcholine, endothelin, angiotensin II, nitroglycerin, and cGMP.³⁴ It appears, therefore, that K_{Ca} modulation may be an important regulatory mechanism of smooth muscle function. K_{Ca} current may not contribute to regulation of resting tension, or its role is minor in the presence of normal intracellular Ca²⁺. 35 Another possible argument for the regulation of resting tension is that a very small number of open K⁺ channels is required for maintenance of resting membrane potential, as suggested by Nelson.²¹ Moreover, because of their high density per smooth muscle cell, large conductance, and the high input resistance, K_{Ca} channels may also contribute to the resting membrane potential.

The delayed rectifier (also called outwardly rectifying) K^+ current (K_{dr}) is voltage and Ca^{2+} dependent. 7,36,37 This current is activated when the potential across sarcolemma is more positive than -40 mV, and plays a dominant role in membrane repolarization and, to a degree, in maintaining the resting potential of aortic smooth muscle. It can be modulated by second messengers and angiotensin II. The activation of these channels at the physiologic range of membrane potential will lead to membrane hyperpolarization and inactivation of L-type Ca^{2+} channels. On the other hand, high levels of these dilators may lead to cGMP-induced

block of L-type Ca²⁺ channels, an effect similar to that produced by isoproterenol.

The ATP-sensitive K^+ channel (K_{ATP}) of smooth muscle is involved in the mechanism of action of many vasodilator substances known as K⁺ channel openers (i.e., pinacidil, minoxidil, nicorandil, and chromokalim).38 These channels are only weakly voltage dependent, and are not influenced by changes in intracellular Ca²⁺. Hyperpolarization produced by the activation of KATP channels will effectively inactivate Ca2+ channels and decrease Ca2+ influx, leading to a lower level of vascular tone. Another characteristic of KATP channel is that it is inhibited by high intracellular ATP and antidiabetic sulfonil urea compounds, such as glibenclamide and tolbutamine, and it is activated by low levels of cytosolic ATP.³⁸ If the concentration of ATP is increased inside the membrane, the Po of KATP channel is reduced. Several hyperpolarizing vasodilators, such as VIP (vasoactive intestinal polypeptide), calcitonin gene-related peptide (CGRP), and acetylcholine, induce release of EDRF and a hyperpolarizing factor from the endothelium that are blocked by glibenclamide. indicating that these vasodilators may also act by opening K_{ATP} channel.³⁹ Endothelium-derived hyperpolarizing factor (EDHF) also has properties of K+ channel openers, although the type of K⁺ channel involved is not known.

An inward rectifier K^+ channel is activated by hyperpolarization of the vascular smooth muscle cells, allowing the inward movement of K^+ . At membrane potentials positive to equilibrium potentials for potassium (E_K at approximately -90 mV), these channels do allow an outward K^+ current and, therefore, may contribute to the resting membrane potential. These channels will

be closed when the vessel is tonically depolarized during increased sympathetic nerve activity.

The time-independent background K⁺ current is sensitive to the external calcium concentration, and may be responsible in setting the level of the resting membrane potential.

Gap Junctions

With increasing metabolic demand of the organ (e.g., exercising muscle) a profound ascending vasodilation occurs within seconds. 40 This coordinated increase in blood flow is probably caused by a flow-dependent endothelial cell-mediated relaxation and smooth muscle cell-to-cell conduction. Unlike skeletal muscle, but similar to cardiac muscle, vascular muscle is coupled by gap junctions, 41,42 which provide a cell-to-cell lowresistance conduction pathway for the functional integration. These junctions are membrane structures that contain aqueous (nonselective) channels, linking the cytoplasm of adjacent cells. Each functional channel is formed by two hemichannels and a 12-identical protein subunit called connexins. They are responsible for equilibration of ionic and small molecular pools between the cells, electrotonic coupling, and coordinated vessel responses to different stimuli. Ca²⁺ and, perhaps, IP₃ can diffuse between smooth muscle cells through gap junction channels. 43 A number of agents, including halothane,44 alcohols, and cGMP, have been shown to decrease junctional conductance in myocardial cells, but an increase is seen in the presence of cAMP. Vascular smooth muscle gap junction conduction is also regulated by second messengers, and it was shown that cAMP is responsible for moderate decreases, and cGMP for no change, in junctional current.41

Anesthetics

Although anesthetics are potent vasodilators, the mechanism of their action is not well understood. Inhalational anesthetics cause vasodilation in specific vascular beds, either by a direct depressant action on the vessel, or by an indirect attenuation of vasoconstrictor activity. In the *in vivo* setting, the mechanism for the altered blood flow to a specific organ during anesthesia is likely to involve interaction among endothelium, vascular smooth muscle, arterial pressure, metabolic requirement of the organ, and the autonomic nervous system. For instance, in the intact coronary

circulation, the direct effects of volatile anesthetics on arterial muscle are superimposed on their dominant depressant action on the myocardium, *i.e.*, reduced cardiac work and oxygen demand. It appears that isoflurane is a more potent coronary vasodilator than halothane in the isolated perfused heart, ⁴⁵ and a less potent dilator of isolated coronary arterial segments. ⁴⁶ In studies on isolated coronary artery rings ⁴⁴ and isolated tetrodotoxin-arrested rat heart, halothane caused direct dilation of coronary vessels without affecting oxygen consumption or extraction. ⁴⁷ Recent results have also shown that isoflurane produces potent dose-dependent relaxation of canine middle cerebral arteries *in vitro*, and that this relaxation is endothelium independent. ⁴⁸

Halothane and isoflurane were found to increase intracellular cAMP in rat aortic smooth muscle. 49 More recent studies have shown that halothane-induced vasodilation of cerebral vessels is partly mediated by an increase in tissue cGMP levels. 50,51 An increase in the cellular cGMP levels induces vascular smooth muscle relaxation by activating cGMP-dependent protein kinase. As indicated previously, in addition to Ca²⁺ and K⁺ channels, cA-PK and cG-PK also phosphorylate the sarcolemmal Ca²⁺-ATPase and Na⁺/Ca²⁺ exchanger, and stimulate the Ca²⁺ pump, and, therefore, can enhance activities of all three Ca2+ removal systems in vascular smooth muscle, producing vasodilation. It was recently shown that the elevations in cGMP in arterial smooth muscle can also uncouple the stress from myosin phosphorylation.⁵² Most tissues have two guanylyl cyclase isoenzymes; a membrane-bound particulate and cytosolic (soluble) enzyme. The soluble enzyme is activated by nitric oxide radicals, and the membrane-bound enzyme is activated by atrial natriuretic factor. An increase in cGMP level induced by halothane results from activation of the particulate, but not soluble, enzyme in canine middle cerebral vessels.⁵⁰ Therefore, along with direct modulation of ion channels, some of the effects of halothane on ion channels may be mediated via an increase in tissue cGMP or cAMP levels.

Halothane and isoflurane were shown to depress agonist-induced inositol phosphate formation and increases in intracellular Ca²⁺ in isolated coronary vessels.⁵³ These anesthetics did not have significant effects on contractions evoked by direct activation of protein kinase C, indicating that they acted at the proximal part of the signal transduction pathway (*i.e.*, receptor or G protein).

In isolated aortic smooth muscle, halothane was shown to slightly decrease maximum Ca²⁺-activated

tension development of the contractile proteins, decrease Ca²⁺ accumulation in the SR, and increase Ca²⁺ release from the SR.⁵⁴ These decreases in cellular Ca²⁺ are probably responsible for the anesthetic-induced attenuation of norepinephrine-induced oscillation in vascular tension that is associated with intracellular calcium fluxes from the SR.⁵⁵

It was reported that halothane attenuates α_2 , but not α_1 , adrenoceptor responsiveness in canine saphenous vein. The results indicated that halothane interferes with α_2 excitation-contraction coupling that is dependent on the influx of extracellular Ca^{2+} . In addition, α_1 -mediated vasoconstriction caused by the release of intracellular Ca^{2+} was far less sensitive to halothane. Recently, the direct effects of halothane, enflurane, and isoflurane were compared on the tension generated in the mesenteric venous smooth muscle. The results indicate that all three agents attenuate contractile responses to exogenous and endogenous NE, with isoflurane being more potent than halothane or isoflurane.

The α_2 -adrenergic agonist, dexmedetomidine, can activate not only α_2 receptors in the central nervous system, but also those in the peripheral vasculature. Current results indicate⁵⁸ that dexmedetomidine has a direct vasoconstrictor effect on coronary and cerebral vasculature *in vitro*, and that this effect may be opposed by simultaneous release of endothelium-derived relaxing factor. Nevertheless, the direct stimulation of α_2 adrenoceptors by dexmedetomidine in these vessels resulted in only minimal vasoconstriction.

Recently, the effects of halothane and isoflurane on macroscopic Ca²⁺ and K⁺ channel currents were investigated in voltage-clamped vascular muscle cells of the canine coronary artery.³⁶ At equianesthetic concentrations, halothane was found to be more potent than isoflurane in suppressing both ionic currents in the coronary arterial cells. Moreover, both anesthetics preferentially reduced Ca²⁺ current. Thus, in the coronary artery, which relies on Ca²⁺ entry for vascular muscle activation, the reduced Ca²⁺ influx may represent one of the mechanisms by which volatile anesthetics induce dilation.

The effects of isoflurane on macroscopic long-lasting type Ca²⁺ and K⁺ channel currents were also investigated in voltage-clamped single canine middle cerebral

artery cells.³⁷ The results indicate that isoflurane reduced the amplitude of K⁺ and Ca²⁺ channel current. and that isoflurane was a more potent blocker of the Ca²⁺ channel current at more negative membrane potentials. A reduction of Ca2+ influx would dilate cerebral arteries, which rely predominantly on the influx of external Ca²⁺ for the maintenance of contraction.⁵⁹ However, the block of K⁺ channel current by isoflurane would favor membrane depolarization, because K⁺ conductance is crucial for repolarization of cell membrane potential and cerebral arterial relaxation. Although this membrane depolarization may initially open voltage-dependent Ca2+ channels, the effective block of Ca²⁺ influx by isoflurane would probably minimize the contribution of these channels to the cytoplasmic Ca²⁺ concentration. Therefore, the simultaneous depression of Ca2+ and K+ currents by isoflurane may cause electromechanical uncoupling of cerebral vascular smooth muscle. For example, halothane caused membrane depolarization despite simultaneous vascular relaxation, indicating uncoupling between the membrane potential and vascular contractions. 60 These results may be caused by the fact that halothane and isoflurane reduced the amplitude of K⁺ and Ca²⁺ currents in the vascular smooth muscle membrane. 36,37 However, the Ca²⁺ current was considerably more sensitive to blockade by volatile anesthetics. In general, contractile mechanisms in cerebral and coronary blood vessels appear to be more dependent on extracellular Ca²⁺ influx than on intracellular stores of Ca²⁺, and, therefore, modulation of Ca2+ influx by volatile anesthetics represents a potential dilator mechanism. In addition, the results of recent studies indicate that volatile anesthetics are more potent direct dilators of cerebral than coronary vascular smooth muscle.35

Preliminary studies from our laboratory indicate that halothane at clinically relevant concentrations can produce hyperpolarization of the resting membrane potential in small mesenteric arteries and veins *in vivo*. The inhibition of inward Ca²⁺ current appears to contribute to this hyperpolarization of the resting membrane potential and, therefore, to a significant direct vasodilatory action of the potent volatile anesthetics.

The effects of halothane and isoflurane were recently examined on Ca²⁺-activated single K⁺ channels in single vascular smooth muscle cells isolated from dog cerebral arteries.† Both halothane and isoflurane reversibly decreased the P_o, mean open time, and frequency of opening of a 99-pS K⁺ channel. The single-channel amplitude or the slope of the current-voltage relationship

[†] Eskinder H, Gebremedhin D, Lee JG, Rusch NJ, Kampine JP, Bosnjak ZJ: Halothane and isoflurane decrease the open state probability of K^+ channels in dog cerebral arterial muscle cells (unpublished data).

was not affected by these anesthetics. From these results, it is evident that a depression of Ca^{2+} -activated K^+ channel does not prevent the anesthetic-induced vasodilation of canine cerebral arteries.

In summary, it appears that anesthetics affect a number of sites that are responsible for direct excitation of vascular smooth muscle, and that the individual responses will vary depending on local vascular activity, concentration, and type of anesthetic; mode and specificity of agonist activation; role of endothelium; and other regulatory factors.

References

- 1. Miller VM: Interactions between neural and endothelial mechanisms in control of vascular tone. News in Physiological Sciences 6:60–63, 1991
- 2. Bolton TB: Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 59:606–718, 1979
- 3. Somlyo AP, Somlyo AV: Vascular smooth muscle. Pharmacol Rev 22:249-353, 1970
- 4. Blatter LA, Wier WG: Agonist-induced [Ca²⁺]₁ waves and Ca²⁺-induced Ca²⁺ release in mammalian vascular smooth muscle cells. Am J Physiol 263:H576–H586, 1992
- 5. Berridge MJ: Inositol triphosphate and diacylglycerol as second messengers. Biochem J 220:345–360, 1984
- 6. Byrne NG, Large WA: Membrane ionic mechanisms activated by noradrenaline in cells isolated from the rabbit portal vein. J Physiol (Lond) 404:557–573, 1988
- 7. Hirst GD, Edwards FR: Sympathetic neuroeffector transmission in arteries and arterioles. Physiol Rev 69:546–604, 1989
- 8. Nelson MT, Standen NB, Brayden JE, Worley JF: Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 336:382–385, 1988
- 9. Wakatsuki T, Nakaya Y, Inoue I: Vasopressin modulates K⁺-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 263:H491–H496, 1992
- 10. Cauvin C, Loutzenhiser R, Van Breemen C: Mechanisms of calcium antagonist-induced vasodilation. Annu Rev Pharmacol Toxicol 23:373–396, 1983
- 11. Ohya Y, Sperelakis N: Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells. Circ Res 68:763–771, 1991
- 12. Ohya Y, Sperelakis N: Agonist modulation of voltage-dependent calcium channels in vascular smooth muscles, Ion Channels of Vascular Smooth Muscle Cells and Endothelial Cells. Edited by Sperelakis N, Kuriyama H. New York, Elsevier, 1991, pp 39–46
- 13. Bkaily G, Peyrow M, Sculptoreanu A, Jacques D, Chahine M, Regoli D, Sperelakis N: Angiotensin II increases I_{sl} and blocks I_K in single aortic cell of rabbit. Pflugers Arch 412:448–450, 1988
- 14. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415, 1988
- 15. Klockner U, Isenberg G: Endothelin depolarizes myocytes from porcine coronary and human mesenteric arteries through a Ca-activated chloride current. Pflugers Arch 418:168–175, 1991

- 16. Chen C, Wagoner PK: Endothelin induces a nonselective cation current in vascular smooth muscle cells. Circ Res 69:447–454, 1991
- 17. Nishimura J, Moreland S, Ahn HY, Kawase T, Moreland RS, van Breemen C: Endothelin increases myofilament Ca^{2+} sensitivity in α -toxin-permeabilized rabbit mesenteric artery. Circ Res 71:951–959, 1992
- 18. Sakata K, Ozaki H, Kwon SC, Karaki H: Effects of endothelin on the mechanical activity and cytosolic calcium level of various types of smooth muscle. Br J Pharmacol 98:483–492, 1989
- 19. Le Monnier de Gouville AC, Lippton HL, Cavero I, Summer WR, Hyman AL: Endothelin: A new family of endothelium-derived peptides with widespread biological properties. Life Sci 45:1499–1513, 1989
- 20. Meninger GA, Davis MJ: Cellular mechanisms involved in the vascular myogenic response. Am J Physiol 263:H647-H659, 1992
- 21. Nelson MT, Patlak JB, Worley JF, Standen NB: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3–C18, 1990
- 22. van Breemen C, Cauvin C, Johns A, Leijten P, Yamamoto H: Ca²⁺ regulation of vascular smooth muscle. Fed Proc 45:2746–2751, 1986
- 23. Vrolix M, Raeymaekers L, Wuytack F, Hofmann F, Casteels R: Cyclic GMP-dependent protein kinase stimulates the plasmalemmal Ca^{2+} pump of smooth muscle via phosphorylation of phosphatidylinositol. Biochem J 255:855–863, 1988
- 24. Lauger P: Voltage dependence of sodium-calcium exchange: Predictions from kinetic models. J Membr Biol 99:1–11, 1987
- 25. Sperelakis N, Ohya Y: Regulation of calcium slow channels in vascular smooth muscle cells, Ion Channels of Vascular Smooth Muscle Cells and Endothelial Cells. Edited by Sperelakis N, Kuriyama H. New York, Elsevier, 1991, pp 27–38
- 26. Bkaily G: Receptor and second messenger modulation of Ca²⁺ and K⁺ channels activity in vascular smooth muscle cells, Ion Channels of Vascular Smooth Muscle Cells and Endothelial Cells. Edited by Sperelakis N, Kuriyama. New York, Elsevier, 1991, pp 185–198
- 27. Rashatwar SS, Cornwell TL, Lincoln TM: Effects of 8-bromocGMP on Ca²⁺ levels in vascular smooth muscle cells: Possible regulation of Ca²⁺-ATPase by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 84:5685–5689, 1987
- 28. Furukawa K-I, Ohshima N, Tawada-Iwata Y, Shigekawa M: Cyclic GMP stimulates ${\rm Na^+/Ca^{2^+}}$ exchange in vascular smooth muscle cells in primary culture. J Biol Chem 266:12337–12341, 1991
- 29. Hume JR, Leblanc N: Macroscopic K⁺ currents in single smooth muscle cells of the rabbit portal vein. J Physiol (Lond) 413:49–73, 1989
- 30. Gelband CH, Hume JR: Ionic currents in single smooth muscle cells of the canine renal artery. Circ Res 71:745–758, 1992
- 31. Langton PD, Nelson MT, Huang Y, Standen NB: Block of calcium-activated potassium channels in mammalian arterial myocytes by tetraethylammonium ions. Am J Physiol 260:H927–H934, 1991
- 32. Renaud JF, Bkaily G, Benabderrazik M, Jacques D, Sperelakis N: Bay K 8644 induce enhancement of K⁺ current in both single heart cell and smooth muscle cell. Mol Cell Biochem 80:73–78, 1988
- 33. Brayden JE, Nelson MT: Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 256:532–535, 1992
- 34. Toro L, Stefani E: Calcium activated $\rm K^+$ channels: Metabolic regulation. J Bioenerg Biomembr 23:561–576, 1991

- 35. Marijic J, Buljubasic N, Coughlan MG, Kampine JP, Bosnjak ZJ: Effect of K⁺ channel blockade with tetraethylammonium on anesthetic-induced relaxation in canine cerebral and coronary arteries. Anesthesiology 77:948–955, 1992
- 36. Buljubasic N, Rusch NJ, Marijic J, Kampine JP, Bosnjak ZJ: Effects of halothane and isoflurane on calcium and potassium channel currents in canine coronary arterial cells. Anesthesiology 76:990–998, 1992
- 37. Buljubasic N, Flynn NM, Marijic J, Rusch NJ, Kampine JP, Bosnjak ZJ: Effects of isoflurane on K⁺ and Ca²⁺ conductance in isolated smooth muscle cells of canine cerebral arteries. Anesth Analg 75: 590–596, 1992
- 38. Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT: Hyperpolarizing vasodilators activate ATP-sensitive K⁺ channels in arterial smooth muscle. Science 245:177–180, 1989
- 39. Nelson MT, Huang Y, Brayden JE, Hescheler J, Standen NB: Arterial dilations in response to calcitonin gene-related peptide involve activation of K^+ channels. Nature 344:770–773, 1990
- 40. Segal SS: Communication among endothelial and smooth muscle cells coordinates blood flow control during exercise. News in Physiological Sciences 7:152–156, 1992
- 41. Moore LK, Beyer EC, Burt JM: Characterization of gap junction channels in A7r5 vascular smooth muscle cells. Am J Physiol 260: C975–C981, 1991
- 42. Larson DM, Haudenschild CC, Beyer EC: Gap junction messenger RNA expression by vascular wall cells. Circ Res 66:1074–1080, 1990
- 43. Christ GJ, Moreno AP, Melman A, Spray DC: Gap junction-mediated intercellular diffusion of Ca²⁺ in cultured human corporal smooth muscle cells. Am J Physiol 263:C373–C383, 1992
- 44. Burt JM, Spray DC: Volatile anesthetics block intercellular communication between neonatal rat myocardial cells. Circ Res 65: 829–837, 1989
- 45. Stowe DF, Marijic J, Bosnjak ZJ, Kampine JP: Direct comparative effects of halothane, enflurane, and isoflurane on oxygen supply and demand in isolated hearts. ANESTHESIOLOGY 74:1087–1095, 1991
- 46. Bollen BA, Tinker JH, Hermsmeyer K: Halothane relaxes previously constricted isolated porcine coronary artery segments more than isoflurane. Ansstriestology 66:748–752, 1987
- 47. Larach DR, Schuler HG, Skeehan TM, Peterson CJ: Direct effects of myocardial depressant drugs on coronary vascular tone: Anesthetic vasodilation by halothane and isoflurane. J Pharmacol Exp Ther 254: 58–64, 1990
 - 48. Flynn NM, Buljubasic N, Bosnjak ZJ, Kampine JP: Isoflurane

- produces endothelium-independent relaxation in canine middle cerebral arteries. Anesthesiology 76:461–467, 1992
- 49. Sprague DH, Yang JC, Ngai SH: Effects of isoflurane and halothane on contractility and the cyclic 3',5'-adenosine monophosphate system in the rat aorta. Anesthesiology 40:162–167, 1974
- 50. Eskinder H, Hillard CJ, Flynn NM, Bosnjak ZJ, Kampine JP: Role of guanylate cyclase-cGMP systems in halothane-induced vasodilation in canine cerebral arteries. Anssthesiology 77:482–487, 1992
- 51. Nakamura K, Hatano Y, Toda H, Nishiwada M, Baek WY, Mori K: Halothane-induced relaxation of vascular smooth muscle: A possible contribution of increased cyclic GMP formation. Jpn J Pharmacol 55:165–168, 1991
- 52. McDaniel NL, Chen XL, Singer HA, Murphy RA, Rembold CM: Nitrovasodilators relax arterial smooth muscle by decreasing [Ca²⁺]₁ and uncoupling stress from myosin phosphorylation. Am J Physiol 263:C461–C467, 1992
- 53. Sill JC, Ozhan M, Nelson R, Uhl C: Isoflurane-, halothane-, and agonist-evoked responses in pig coronary arteries and vascular smooth muscle cells, Mechanisms of Anesthetic Action in Skeletal, Cardiac, and Smooth Muscle. Edited by Blanck TJJ, Wheeler DM. New York, Plenum, 1991, pp 257–269
- 54. Su JY, Zhang CC: Intracellular mechanisms of halothane's effect on isolated aortic strips of the rabbit. Anesthesiology 71:409–417, 1989
- 55. Marijic J, Madden JA, Kampine JP, Bosnjak ZJ: The effects of halothane on norepinephrine responsiveness in rabbit small mesenteric veins. Anssthesiology 73:479–484, 1990
- 56. Larach DR, Schuler HG, Derr JA, Larach MG, Hensley FA, Zelis R: Halothane selectively attenuates α_2 -adrenoceptor mediated vasoconstriction, *in vivo* and *in vitro*. Anistriesiology 66:781–791, 1987
- 57. Stadnicka A, Flynn NM, Bosnjak ZJ, Kampine JP: Enflurane, halothane and isoflurane attenuate contractile responses to exogenous and endogenous norepinephrine in isolated small mesenteric veins of the rabbit. ANESTHESIOLOGY 78:326–334, 1993
- 58. Coughlan MG, Lee JG, Bosnjak ZJ, Schmeling WT, Kampine JP, Warltier DC: Direct coronary and cerebral vascular responses to dexmedetomidine: Significance of endogenous nitric oxide synthesis. Anesthesiology 77:998–1006, 1992
- 59. Bevan JA, Bevan RD: Arterial wall changes in chronic cerebrovasospasm: In vitro and in vivo pharmacological evidence. Annu Rev Pharmacol Toxicol 28:311–329, 1988
- 60. Harder DR, Gradall K, Madden JA, Kampine JP: Cellular actions of halothane on cat cerebral arterial muscle. Stroke 16:680–683, 1985